HISUN(SH:600267) Xin Lang Cai Jing·2025-09-16 10:56Core Viewpoint - The company, Haizheng Pharmaceutical (600267.SH), has signed an exclusive licensing and strategic cooperation agreement with Shenzhen Aixin Dawei Pharmaceutical Technology Co., Ltd. to introduce the globally innovative small molecule prodrug AST-3424 in specified regions [1] Group 1 - The company will pay an upfront fee to Aixin Dawei and will also pay milestone payments based on the actual achievement of development milestones, with total costs not exceeding 240 million yuan [1] - The cooperation area includes mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region [1] - The company will also engage in strategic cooperation with Aixin Dawei on the AKR1C3 enzyme activation platform [1]